Zika Virus Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, zika virus testing market size in 2026 is estimated at USD 256.03 million, growing from 2025 value of USD 239.21 million with 2031 projections showing USD 359.44 million, growing at 7.03% CAGR over 2026-2031.

This report is Segmented by Test Type (Molecular Tests, Serologic Tests, PRNT), Sample Type (Blood/Serum, Urine, Saliva & Others), End-User (Hospitals & Clinics, Public-Health/Diagnostic Laboratories, Point-Of-Care Settings & Home Testing, Research Institutes), and Geography (North America, South America, Europe, APAC, Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Zika Virus Testing Market Trends and Insights

Rising Incidence of Zika Outbreaks

Pan American Health Organization recorded 40,891 confirmed cases in 2024, a 14% jump from 2023, confirming the virus's endemic status in tropical belts. Predictable seasonal surges spur hospitals to procure rapid molecular cartridges that distinguish Zika from dengue and chikungunya during triage. Brazil remains the epicenter at 84% of regional cases, while emergent clusters in Argentina and Colombia widen geographic test uptake. WHO guidance urges laboratories to maintain baseline capacity between epidemics, stabilizing annual reagent demand.

Government Surveillance & Funding

Sustained public investment is anchoring the Zika virus testing market. The CDC's Epidemiology and Laboratory Capacity program ring-fenced vector-borne allocations for FY 2025, guaranteeing reagent purchases for state labs. The World Bank's Pandemic Fund channeled USD 16 million to Caribbean nations to bolster integrated arboviral surveillance networks. NIAID's 2025 budget narrative earmarks diagnostics R&D, signalling multiyear funding visibility that reassures manufacturers of volume commitments.

Declining Epidemic Momentum

Inter-epidemic lulls curb routine testing volumes as clinical suspicion wanes and budgets shift elsewhere. WHO's May 2024 update flagged subdued case counts outside hotspots, prompting some laboratories to run down reagent stocks. Manufacturers bridge the demand trough with multiplex panels that preserve cartridge turnover even when Zika incidence dips, yet revenue variability remains a headwind.

Other drivers and restraints analyzed in the detailed report include:

1. Advances in RT-PCR & Multiplex NAAT
2. POC Test Integration into ID Panels
3. Cross-reactivity with Dengue Antibodies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Molecular assays delivered 58.12% revenue in 2025, underscoring their primacy in acute-phase diagnosis. The Zika virus testing market size for point-of-care molecular platforms is forecast to expand at 8.55% CAGR through 2031, supported by CLIA-waived systems that slot into emergency rooms and obstetric clinics. The Zika virus testing market share for serology trails due to dengue cross-reactivity, though population-level IgM surveys sustain baseline demand. Isothermal amplification and AI-curated primers are shrinking run times and manual steps, enhancing scalability in resource-constrained laboratories.

Second-generation LAMP cartridges leverage lyophilized reagents for ambient shipping, lowering cold-chain costs. Digital PCR is emerging for low-prevalence surveillance, offering femtogram-level sensitivity suited to blood-bank screening. PRNT remains reference-grade yet limited to a handful of BSL-3 centers, constraining its commercial footprint. Serology firms are pivoting toward epitope-engineered antigens to claw back specificity, but molecular dominance is unlikely to be challenged within the forecast window.

Complete Report Scope:

• By Test Type (Value)
  • Molecular Tests (RT-PCR, NAAT)
  • Serologic Tests (IgM/IgG ELISA)
  • Plaque-Reduction Neutralisation Test (PRNT)
• By Sample Type (Value)
  • Blood / Serum
  • Urine
  • Saliva & Others
• By End-User (Value)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Home care Settings
  • Research Institutes
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America's 41.88% revenue in 2025 reflects CDC grant flows and rapid Emergency Use Authorizations that de-risk vendor investment. The Zika virus testing market size in the region will advance steadily as travel-linked importations sustain screening in blood banks and fertility clinics. Federal stockpiles guarantee reagent turnover even during low-incidence years.

Asia-Pacific leads in growth at 7.08% CAGR as governments mainstream arboviral surveillance within universal healthcare expansions. Climate-driven Aedes range shifts toward temperate latitudes spur Japan, South Korea, and northern China to adopt early-warning molecular platforms. Urban megacities in India and Indonesia are piloting saliva kiosks that transmit real-time positives to municipal dashboards.

South America, anchored by Brazil, remains the epidemiological hotspot that drives bulk cartridge demand. PAHO-coordinated reagent tenders create price stability for regional labs while cross-training programs standardize assay performance. Europe focuses on traveler testing and antenatal screening in Mediterranean mosquito zones. Harmonization under IVDR is accelerating adoption of multiplex CE-marked panels.

The Middle East and Africa exhibit nascent but fast-rising demand as vector surveillance gains donor support. Nigeria's National Arbovirus Laboratory Network installed its first high-throughput NAAT line in 2024, signaling emerging opportunities. Gulf nations procure diagnostics to screen migrant labor inflows, adding a travel-linked revenue stream.

1. Roche
2. Abbott Laboratories
3. Thermo Fisher Scientific
4. Quest Diagnostics
5. ARUP Laboratories
6. Eurofins
7. DiaSorin
8. Chembio Diagnostics
9. Hologic
10. Luminex
11. Siemens Healthineers
12. Altona Diagnostics
13. Creative Diagnostics
14. InBios International
15. Biocan Diagnostics
16. QIAGEN
17. bioMerieux
18. Bio-Rad Laboratories

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support